Exagen Inc. logo

Exagen Inc.

XGN

NASDAQHealthcareMedical - Diagnostics & Research

Regular session

$7.6501

+$0.0001 · +0.00%

Aug 25, 12:20 PM ETData delayed

XGN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

31

Weakening

Sentiment

58

Mixed

Risk resilience

22

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
John Aballi
Listed since
Sep 19, 2019
Employees
216

Market position

Day range

Current $7.6501

52-week range

Current $7.6501

Open
$7.68
Previous close
$7.65
Volume
59.53K
0.15× average
Average volume
399.56K
Average daily volume
Market cap
184.82M USD
Beta
2.03
Market reference 1
50-day average
$5.2521
+45.66% above average
200-day average
$4.8686
+57.13% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
124.56M USD
P/E (TTM)
-9.33×
P/B (TTM)
15.13×
P/S (TTM)
2.6×
EV / EBITDA
-9.25×
Earnings yield
-15.22%
Free cash flow yield
-10.88%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
58.64%
Operating margin
-18.58%
Net margin
-26.61%
Return on equity
-114.34%
Return on assets
-34.39%
Return on invested capital
-30.02%

Financial health

Debt / equity
2.09×
Current ratio
3.45×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends76%10%-55%-120%Gross margin, FY2021: 57.37%Gross margin, FY2022: 46.86%Gross margin, FY2023: 56.06%Gross margin, FY2024: 59.51%Gross margin, FY2025: 58.28%Operating margin, FY2021: -49.83%Operating margin, FY2022: -101.07%Operating margin, FY2023: -43.46%Operating margin, FY2024: -24.51%Operating margin, FY2025: -21.13%Net margin, FY2021: -55.59%Net margin, FY2022: -104.00%Net margin, FY2023: -45.08%Net margin, FY2024: -27.17%Net margin, FY2025: -29.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 57.37%. Gross margin FY2022 46.86%. Gross margin FY2023 56.06%. Gross margin FY2024 59.51%. Gross margin FY2025 58.28%. Operating margin FY2021 -49.83%. Operating margin FY2022 -101.07%. Operating margin FY2023 -43.46%. Operating margin FY2024 -24.51%. Operating margin FY2025 -21.13%. Net margin FY2021 -55.59%. Net margin FY2022 -104.00%. Net margin FY2023 -45.08%. Net margin FY2024 -27.17%. Net margin FY2025 -29.97%.

Income trends

Revenue

66.58M USD+19.65%

Operating income

−14.07M USD-3.18%

Net income

−19.95M USD-31.99%
Income trends across reported periods77.97M USD32.39M USD−13.2M USD−58.78M USDRevenue, FY2021: 48.3M USDRevenue, FY2022: 45.56M USDRevenue, FY2023: 52.55M USDRevenue, FY2024: 55.64M USDRevenue, FY2025: 66.58M USDOperating income, FY2021: −24.07M USDOperating income, FY2022: −46.05M USDOperating income, FY2023: −22.84M USDOperating income, FY2024: −13.64M USDOperating income, FY2025: −14.07M USDNet income, FY2021: −26.85M USDNet income, FY2022: −47.39M USDNet income, FY2023: −23.69M USDNet income, FY2024: −15.12M USDNet income, FY2025: −19.95M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 48.3M USD. Revenue FY2022 45.56M USD. Revenue FY2023 52.55M USD. Revenue FY2024 55.64M USD. Revenue FY2025 66.58M USD. Operating income FY2021 −24.07M USD. Operating income FY2022 −46.05M USD. Operating income FY2023 −22.84M USD. Operating income FY2024 −13.64M USD. Operating income FY2025 −14.07M USD. Net income FY2021 −26.85M USD. Net income FY2022 −47.39M USD. Net income FY2023 −23.69M USD. Net income FY2024 −15.12M USD. Net income FY2025 −19.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue66.58M USD55.64M USD52.55M USD45.56M USD48.3M USD
Cost of goods sold27.78M USD22.53M USD23.09M USD24.21M USD20.59M USD
Gross profit38.8M USD33.11M USD29.46M USD21.35M USD27.71M USD
Research and development6.25M USD5.38M USD4.87M USD9.88M USD7.24M USD
Selling, general, and administrative46.62M USD41.37M USD47.43M USD52.02M USD44.54M USD
Operating expenses52.87M USD46.75M USD52.29M USD67.4M USD51.78M USD
Interest income289K USD767K USD1.52M USD830K USD16K USD
Interest expense4.32M USD2.23M USD2.34M USD2.45M USD2.63M USD
Depreciation and amortization2.12M USD1.72M USD2.17M USD1.56M USD948K USD
Operating income−14.07M USD−13.64M USD−22.84M USD−46.05M USD−24.07M USD
Net income−19.95M USD−15.12M USD−23.69M USD−47.39M USD−26.85M USD

Company facts updated Aug 25, 2026.

Earnings

EPS beat rate
64%
7 beats, 1 miss, 3 met estimates
Average EPS surprise
+11.70%
11 comparable reports
Latest EPS result
-0.13
Estimate -0.19 · Beat by 32.09%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.11-0.19-0.27-0.35Q1 '25BeatQ2 '25MetQ3 '25MetQ4 '25MissQ1 '26MetQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -0.2, estimate -0.27, surprise +25.93%, Beat. Q2 2025, reported May 5, 2025: actual -0.2, estimate -0.2, surprise 0.00%, Met estimate. Q3 2025, reported Jul 29, 2025: actual -0.18, estimate -0.18, surprise 0.00%, Met estimate. Q4 2025, reported Nov 4, 2025: actual -0.31, estimate -0.157, surprise -97.57%, Miss. Q1 2026, reported Mar 10, 2026: actual -0.2, estimate -0.2, surprise 0.00%, Met estimate. Q2 2026, reported May 11, 2026: actual -0.17, estimate -0.24, surprise +29.17%, Beat. Q3 2026, reported Aug 4, 2026: actual -0.13, estimate -0.191, surprise +32.09%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.19, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates20.74M18.11M15.48M12.86MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 13.66M USD, estimate 14.57M USD, surprise -6.26%, Miss. Q2 2025, reported May 5, 2025: actual 15.5M USD, estimate 14.55M USD, surprise +6.49%, Beat. Q3 2025, reported Jul 29, 2025: actual 17.2M USD, estimate 16.9M USD, surprise +1.78%, Beat. Q4 2025, reported Nov 4, 2025: actual 17.24M USD, estimate 16.88M USD, surprise +2.14%, Beat. Q1 2026, reported Mar 10, 2026: actual 16.63M USD, estimate 16.57M USD, surprise +0.37%, Beat. Q2 2026, reported May 11, 2026: actual 17.31M USD, estimate 16.41M USD, surprise +5.47%, Beat. Q3 2026, reported Aug 4, 2026: actual 19.94M USD, estimate 17.8M USD, surprise +12.03%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 18.34M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.50

11.11% upside
Past 12 months12-month forecastHigh $10.00Average $8.50Low $8.00

Rating distribution

10 ratings
Strong buy00%
Buy10100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

7 institutions
Craig-HallummaintainBuy

XGN news

XGN peers

ETFs holding XGN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research XGN

research.disclaimer